| Single-chain bifunctional vascular endothelial growth factor (VEGF)-follicle-stimulating hormone (FSH)-C-terminal peptide (CTP) is superior to the combination therapy of recombinant VEGF plus FSH-CTP in stimulating angiogenesis during ovarian folliculogenesis. | |
| | |
MedLine Citation:
|
PMID: 17122074 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Infertility technologies often employ exogenous gonadotropin therapy to increase antral follicle production. In an effort to enhance ovarian response, several long-acting FSH therapies have been developed including an FSH-C-terminal peptide (CTP), where the FSH subunits are linked by the CTP moiety from human chorionic gonadotropin, which is responsible for the increased half-life of human chorionic gonadotropin. We found that administration of FSH-CTP for ovarian hyperstimulation in rats blunted ovarian follicle vascular development. In women, reduced ovarian vasculature has been associated with lower pregnancy rates. We were interested in determining whether vascular endothelial growth factor (VEGF) therapy could enhance ovarian angiogenesis in FSH-CTP-treated rats. Coadministration of systemic FSH-CTP plus recombinant VEGF was compared with treatment with a novel, single-chain bifunctional VEGF-FSH-CTP (VFC) analog. For VFC, the FSH portion targets the protein to the ovary and stimulates follicle growth, whereas VEGF enhances local vascular development. Both in vitro and in vivo studies confirm the dual FSH and VEGF action of the VFC protein. Evaluation of ovarian follicle development demonstrates that administration of combination therapy using VEGF and FSH-CTP failed to increase follicle vasculature above levels seen with FSH-CTP monotherapy. However, treatment with VFC significantly increased follicle vascular development while concurrently increasing the number of large antral follicles produced. In conclusion, we report the production and characterization of a long-acting, bifunctional VEGF-FSH-CTP protein that is superior to combination therapy for enhancing VEGF activity in the ovary and stimulating follicular angiogenesis in rats. |
| | |
Authors:
|
Rhonda K Trousdale; Susan V Pollak; Jeffrey Klein; Leslie Lobel; Yasuhiro Funahashi; Nikki Feirt; Joyce W Lustbader |
Related Documents
:
|
2589084 - Photoperiodic ovarian response in yellow-throated sparrow, gymnorhis xanthocollis: invo... 15763914 - Primary psoas muscle abscess diagnosed and treated during pregnancy: case report and li... 11255554 - Advances in ultrasound assessment in the establishment and development of pregnancy. 23562084 - Twenty-five years of fetal echocardiography in conjoined twins: lessons learned. 20950254 - Patterns of iodine intake and urinary iodine concentrations during pregnancy and blood ... 6666714 - The sentiments of love and aspirations for marriage and their association with teenage ... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2006-11-22 |
Journal Detail:
|
Title: Endocrinology Volume: 148 ISSN: 0013-7227 ISO Abbreviation: Endocrinology Publication Date: 2007 Mar |
Date Detail:
|
Created Date: 2007-02-16 Completed Date: 2007-04-04 Revised Date: 2007-12-03 |
Medline Journal Info:
|
Nlm Unique ID: 0375040 Medline TA: Endocrinology Country: United States |
Other Details:
|
Languages: eng Pagination: 1296-305 Citation Subset: AIM; IM |
Affiliation:
|
Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York City, NY 10032, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Animals, Newborn CHO Cells Cricetinae Cricetulus Drug Combinations Drug Evaluation, Preclinical Female Fertility Agents, Female / therapeutic use Follicle Stimulating Hormone / chemistry, therapeutic use* Half-Life Infertility, Female / drug therapy, pathology Neovascularization, Physiologic / drug effects* Ovarian Follicle / blood supply*, drug effects, growth & development*, pathology Peptide Fragments / therapeutic use Rats Recombinant Fusion Proteins / chemical synthesis, therapeutic use* Recombinant Proteins / therapeutic use* Vascular Endothelial Growth Factor A / chemistry, therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
DK 063224/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Drug Combinations; 0/Fertility Agents, Female; 0/Peptide Fragments; 0/Recombinant Fusion Proteins; 0/Recombinant Proteins; 0/Vascular Endothelial Growth Factor A; 9002-68-0/Follicle Stimulating Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhib...
Next Document: Adrenal 20alpha-hydroxysteroid dehydrogenase in the mouse catabolizes progesterone and 11-deoxycorti...